COMP <GO>
AKTS vs KURA // RETURN ON INVESTED CAPITAL (ROIC)
Aktis Oncology Inc. (NASDAQ) VS. Kura Oncology Inc. (NASDAQ) • 15-METRIC TALLY: AKTS 0
— KURA 2
■ METRIC PARITY
LAST: $16.85 (+0.18%) • MKT CAP: $937.2M
roic
—
LAST: $10.56 (-1.49%) • MKT CAP: $939.4M
roic
-35.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (AKTS VS. KURA)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | AKTS | KURA | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | — | -35.00% | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | -7.53% | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | -60.00% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | -60.00% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | 25.20% | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 0.20 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | — | 4/9 | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 36.4 | 49.0 | -12.64 | KURA | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $937.2M | $939.4M | -$2.2M | KURA | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | AKTS REV | KURA REV | AKTS GROSS % | KURA GROSS % | AKTS FCF | KURA FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $67.5M | — | — | — | -$70.7M |
| FY 2024 | — | $53.9M | — | — | — | $133.8M |
| FY 2023 | — | $0 | — | — | — | -$124.8M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
AKTS // BETA —
KURA // BETA —